Pharma Mergers Could Stifle Drug Innovation: AAI

Law360, New York (April 9, 2009, 12:00 AM EDT) -- Troubled by consolidation in the pharmaceutical industry, the American Antitrust Institute has called on federal regulators to thoroughly examine the consequences of the proposed Pfizer Inc.-Wyeth Inc. and Merck & Co.-Schering-Plough Corp. tie-ups and their broader systemic effects on competition and creativity.

The AAI sent a memorandum on Tuesday to the Federal Trade Commission, urging the agency to consider the far-reaching competitive effects of Pfizer’s $68 billion bid to acquire Wyeth, and Merck’s $41 billion takeover proposal of Schering-Plough, warning that they could harm drug innovation,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.